Clinical Trial Update: Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients [Phase 4]

View source ↗

Summary

Phase 4 pharmacokinetic study of ceftazidime in intermittent hemodialysis patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Renal Failure

Drugs mentioned

• ceftazidime (ceftazidime)

Snippet

Sponsor: Midwestern University | Conditions: Renal Failure | Phase 4 | Status: WITHDRAWN